HERON THERAPEUTICS, INC. /DE/

HRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000818033

Price chart

Open-market purchases and sales by HRTX insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Aug 12, 20256:00 PM ETAug 8, 2025Rubric Capital Management LP and 1 other10% OwnerPPurchaseCommon Stock, par value $0.01 per share ("Common Stock")+2.39M$1.50+$3.58M29.1M+8.9%SEC
Aug 12, 20256:00 PM ETAug 8, 2025Rubric Capital Management LP and 1 other10% OwnerPPurchaseConvertible Senior Unsecured Promissory Notes ("Notes") · Derivative–––––SEC
Aug 12, 20256:00 PM ETAug 8, 2025Rubric Capital Management LP and 1 other10% OwnerPPurchaseCommon Stock · Derivative+946.1K$1.50+$1.42M94.61K–SEC
Aug 12, 2025Aug 8, 2025Morgan AdamDirectorPPurchaseCommon Stock+1.77M$1.50+$2.65M8.75M+25.3%SEC
Aug 12, 2025Aug 8, 2025Morgan AdamDirectorPPurchaseCommon Stock · Derivative+700.12K$1.50+$1.05M70.01K–SEC

The largest institutional positions in HRTX at the end of Q2 2026.

Institutions holding HRTX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Rubric Capital Management LP30,046,828$12.82M0.12%00.0%Unchanged
Clearline Capital LP11,383,961$4.86M0.31%−851,278−7.0%Reduced
BlackRock, Inc.10,550,750$4.5M0.00%+444,328+4.4%Added
Velan Capital Investment Management LP8,753,290$3.74M2.29%00.0%Unchanged
VANGUARD CAPITAL MANAGEMENT LLC7,782,741$3.32M0.00%−27,588−0.4%Reduced